Quarterly report [Sections 13 or 15(d)]

EQUITY (Tables)

v3.26.1
EQUITY (Tables)
3 Months Ended
Mar. 31, 2026
Equity [Abstract]  
Schedule of Warrants Outstanding and Exercisable The following table summarizes the status of warrants and related transactions:
Non-Derivative (Equity) Warrants
Derivative Liabilities Warrants
Total Number of Warrants Weighted - Average Exercise Price
Balance as of January 1, 2026
57,994,087 21,400,000 79,394,087 $ 0.95 
Balance as of March 31, 2026
57,994,087 21,400,000 79,394,087 $ 0.95 
Exercisable as of March 31, 2026
56,624,087 21,400,000 78,024,087 $ 0.96 
Schedule of Stock Options Outstanding
The following table summarizes the status of stock options and related transactions:
Number of Stock Options Weighted-Average Per Share Exercise Price
Issued and Outstanding as of January 1, 2026 26,597,918  $ 0.75 
Cancelled/forfeited/expired (56,666) $ 0.66 
Issued and Outstanding as of March 31, 2026 26,541,252  $ 0.75 
Exercisable as of March 31, 2026 19,465,889  $ 0.83 
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions The following assumptions were used for the calculation at date of grant:
Three Months Ended March 31,
2026 2025
Weighted average stock price $0.29
Weighted average expected stock price volatility 92.0%
Expected annual dividend yield 0%
Weighted average expected life 5.0 years
Weighted average risk-free annual interest rate 4.0%
Weighted average grant date fair value $0.21
Schedule of Components of Share-based Compensation Expense
The components of share-based compensation expense, net, are as follows:
Three Months Ended March 31,
2026 2025
Stock options expense (forfeiture)
$ 265  $ (381)
Restricted stock 68  — 
Warrants 59  74 
Total share-based compensation expense (forfeiture), net
$ 392  $ (307)